Artrya (ASX:AYA) submitted its response to the US Food and Drug Administration's queries about its regulatory approval application for its Salix coronary anatomy product, according to a Friday Australian bourse filing.
The technological product uses deep-learning algorithms to predictively diagnose potential acute coronary events, the company informed in an earlier filing.
The company did not specify the nature of the queries.
The company's shares rose 2% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。